{{product.productLabel}} {{product.model}}
{{#if product.featureValues}}{{product.productPrice.formattedPrice}} {{#if product.productPrice.priceType === "PRICE_RANGE" }} - {{product.productPrice.formattedPriceMax}} {{/if}}
{{#each product.specData:i}}
{{name}}: {{value}}
{{#i!=(product.specData.length-1)}}
{{/end}}
{{/each}}
{{{product.idpText}}}
{{product.productLabel}} {{product.model}}
{{#if product.featureValues}}{{product.productPrice.formattedPrice}} {{#if product.productPrice.priceType === "PRICE_RANGE" }} - {{product.productPrice.formattedPriceMax}} {{/if}}
{{#each product.specData:i}}
{{name}}: {{value}}
{{#i!=(product.specData.length-1)}}
{{/end}}
{{/each}}
{{{product.idpText}}}
Sample volume: min 18.0 ml
... room temperature. It allows, from a single sample, in addition to cytopathological exams, the processing of other molecular tests for STIs. ...
Result display time: 4 h
... Different pathological types of thyroid nodules (tumors) exhibit significant differences in their biological behavior. From benign thyroid adenomas and indeterminate thyroid nodules to thyroid ...
SPACEGEN
Result display time: 4 h
... and treatment of hereditary thyroid cancer. Both FDA and NMPA have approved a variety of targeted drugs for the treatment of unresectable, recurrent and refractory differentiated thyroid cancer ...
SPACEGEN
... malignant thyroid FNA samples. RET fusion also has a suggestive effect on the efficacy of targeted therapy. In 2020, the FDA successively approved Selpercatinib and Pralsetinib for the systemic treatment of RET fusion-positive thyroid ...
SPACEGEN
... patients. Regulatory status - IVD-CDx Mutation variants - 2 Storage Temp - -20°C (+/- 3°C) 1 well-reaction/ test (24 tests/ kit) ...
the best suppliers